Reassuring safety data from the UK multicomponent meningococcal group B vaccine (4CMenB) programme

2018 ◽  
Vol 2 (6) ◽  
pp. 380-381 ◽  
Author(s):  
Julie A Bettinger
Keyword(s):  
Safety Data ◽  
Meningococcal Group ◽  
Group B ◽  
The Uk

First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England

2020 ◽  
Author(s):  
Shamez N Ladhani ◽  
Helen Campbell ◽  
Nick Andrews ◽  
Sydel R Parikh ◽  
Joanne White ◽  
...  
Keyword(s):  
Real World ◽  
Disease Surveillance ◽  
Age Cohorts ◽  
Poisson Models ◽  
Real World Evidence ◽  
Meningococcal Group ◽  
Adjusted Incidence Rate ◽  
Group B ◽  
The Uk ◽  
Adjusted Incidence

Abstract Background 4CMenB is a protein-based meningococcal B vaccine, but the vaccine antigens may be present on non–group B meningococci. In September 2015, the UK implemented 4CMenB into the national infant immunization program, alongside an emergency adolescent meningococcal ACWY (MenACWY) program to control a national outbreak of group W (MenW) disease caused by a hypervirulent strain belonging to the ST-11 clonal complex. The adolescent program aimed to provide direct protection for adolescents and indirect protection across the population. Methods Public Health England conducts meningococcal disease surveillance in England. MenW cases confirmed during 4 years before and 4 years after implementation of both vaccines were analyzed. Poisson models were constructed to estimate direct protection against MenW disease offered by the infant 4CMenB program along with the indirect impact of the adolescent MenACWY program in children eligible for 4CMenB but not MenACWY. Results Model estimates showed 69% (adjusted incidence rate ratio [aIRR], .31; 95% CI, .20–.67) and 52% (aIRR, .48; 95% CI, .28–.81) fewer MenW cases than predicted among age-cohorts that were fully- and partly-eligible for 4CMenB, respectively. There were 138 MenW cases in <5-year-olds. 4CMenB directly prevented 98 (95% CI, 34–201) cases, while the MenACWY program indirectly prevented an additional 114 (conservative) to 899 (extreme) cases over 4 years. Disease severity was similar in 4CMenB-immunized and unimmunized children. Conclusions This is the first real-world evidence of direct protection afforded by 4CMenB against MenW:cc11 disease. 4CMenB has the potential to provide some protection against all meningococcal serogroups.

Efficacy and safety data for the Ab interno XEN45 gel stent implant at 3 Years: A retrospective analysis

2021 ◽  
pp. 112067212110143
Author(s):  
Itay E Gabbay ◽  
Mordechai Goldberg ◽  
Felicity Allen ◽  
Zhiheng Lin ◽  
Christine Morley ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Failure Rate ◽  
Open Angle Glaucoma ◽  
Safety Data ◽  
Angle Closure ◽  
Efficacy And Safety ◽  
Antihypertensive Medications ◽  
Uk National Health Service ◽  
The Uk ◽  
Comparative Audit

Purpose: To report efficacy and safety measures of the XEN45 gel stent at 36 months in the UK National Health Service setting. Methods: Retrospective non-comparative audit of the records of patients who underwent XEN45 implantation between June 2015 and May 2017 was performed. Main outcome measures were intraocular pressure and number of antihypertensive medications used. Failure was defined as need for further surgery or stent removal. Success was defined as a 20% decrease in intraocular pressure without the need for additional glaucoma medications or a reduction in antihypertensive medications without an increase in baseline intraocular pressure. Needling rates and preoperative factors effect were assessed. Results: The cohort included 205 patients (205 eyes) with primary open angle glaucoma (84.4%), angle closure glaucoma (7.8%), or refractory glaucoma (7.8%), 62.9% had a stand-alone procedure and 37.1%, a combined phaco-XEN45 procedure. Mean intraocular pressure was 22.6 ± 7.0 mmHg at baseline compared to 14.7 ± 3.8 mmHg at 24 months and 14.0 ± 2.9 mmHg at 36 months ( p < 0.001 for both). Mean number of medications used was 2.6 ± 1.1 at baseline compared to 0.5 ± 0.9 and 0.6 ± 1.0, at 24- and 36-months, respectively ( p < 0.001 for both). The failure rate at 36 months was 25%. Needling was required in 36.6%. Evaluation of background factors yielded an increased failure rate in non-Caucasians compared to Caucasians (74% vs 21%, p < 0.001). Conclusion: XEN45 implantation is effective and safe at 36 months’ follow-up. Patients should be advised regarding the risk of failure and possible need for bleb revisions. Careful patient selection may be required.

Antigenicity of meningococcal group B oligo- and polysaccharides of defined chain length

1988 ◽  
pp. 147-152
Author(s):  
M. R. Lifely ◽  
U. T. Nowicka ◽  
E. Krambovitis ◽  
J. Esdaile
Keyword(s):  
Chain Length ◽  
Meningococcal Group ◽  
Group B

scholarly journals A Study of How Urology Out-Patients like to Receive Clinical Information

2006 ◽  
Vol 88 (6) ◽  
pp. 579-582 ◽  
Author(s):  
DN Wood ◽  
A Deshpande ◽  
M Wijewardena ◽  
SS Gujral
Keyword(s):  
General Practitioners ◽  
Clinical Information ◽  
Postal Questionnaire ◽  
Department Of Health ◽  
The Future ◽  
Group A ◽  
Group B ◽  
The Uk ◽  
To Receive ◽  
B 52

INTRODUCTION As part of the NHS Plan the UK Department of Health has suggested that both patients and general practitioners (GPs) are written to following hospital consultations. We audited the responses of patients and GPs to this practice. PATIENTS AND METHODS A total of 160 patients in one consultant urologist's clinic were included. The consultant had never routinely copied GP letters to patients. The SpR in the same clinic had routinely done so in previous posts. Patients who had received letters (group A) and those who had not (group B) were asked to complete a postal questionnaire. GPs were also sent a questionnaire to assess their opinion. The responses were analysed. RESULTS Questionnaires were sent out to patients (80 to group A and 80 to group B. From this, 100 (62.5%) responses were received (A 48 [60%]; B 52 [65%]). Of respondents, 81% were male. Overall, 98% of those patients who received a letter agreed with its contents, and stated they would keep the letter and take it to a subsequent doctor's appointment. Of respondents, 83% (A) and 96% (B) had never received a doctor's letter before but 83% (40 [83%, A], 43 [83%, B]; P > 0.05) of respondents would like to receive doctors' letters in the future. some 22 GP practices received and completed questionnaires at a PCT meeting and 74% of GPs agreed with the practice of copying patients their letters. CONCLUSIONS The results of this study suggest that patients should be offered a copy of their letter and that their response should be documented in the notes. This may serve to improve communication with the patient but should not be undertaken without their agreement.

Meningococcal ACWY vaccine uptake and awareness among student freshers enrolled at Northern Ireland universities

2017 ◽  
Vol 0 (0) ◽  
Author(s):  
Peter J.A. Moore ◽  
B. Cherie Millar ◽  
John E. Moore
Keyword(s):  
Northern Ireland ◽  
University Students ◽  
Vaccination Programme ◽  
Vaccination Campaign ◽  
Vaccine Uptake ◽  
Meningococcal Group ◽  
Males And Females ◽  
The Uk ◽  
Communication Modalities ◽  
First Time

Abstract A new MenACWY conjugate meningococcal vaccination programme was introduced in Northern Ireland (NI) in August 2015, for 13–18 year olds, as well as for first-time university entrants up to 25 years. This reflected the response made by Public Health England, due to the recent rapid increase of meningococcal group W (MenW) disease and on advice of the UK Joint Committee on Vaccination and Immunisation (JCVI). The aims of this study were to evaluate (i) the uptake of the MenACWY vaccine among first-time university students, (ii) vaccine and meningitis awareness, (iii) optimal communication modalities via a multidisciplinary team (MDT) model and (iv) current international vaccination policies relating to non-UK students. A survey was completed by 1210 students, 868 first-time freshers and 342 non-freshers, from healthcare-related, non-healthcare-related and engineering/computing faculties. The survey included an anonymous questionnaire and consented students were aged 17–50 years with a 2:3 ratio of male:female. Vaccine uptake amongst 18-year-old students was 90.7% and 87.3% in female and male cohorts, respectively, falling to 72.1% and 67.7% (19-year cohort) and 32.7% and 39.6% (20- to 25-year cohort) in males and females, respectively. Students reported that posters, clinics and talks were the preferred methods of communication and not social media. There was general lack of awareness of the signs/symptoms of meningitis and approximately 30% of students falsely believed that administration of the MenACWY vaccine excluded the risk of contracting meningitis. Overall, there was a successful vaccination campaign; however, there was a lack of meningitis awareness. Due to differing international meningococcal vaccination schedules, international students enrolling at UK universities need to be informed about current UK policies. For the successful introduction of any vaccination programme amongst university students, it is fundamental that a MDT is established to inform and deliver such a programme in an efficient and timely manner.

Sign in / Sign up

Export Citation Format

Share Document